Hjem › Leukemi
Kliniske studier for Leukemi rekrutterer i USA
102 studier for Leukemi rekrutterer deltakere på steder over hele USA.
Byer med flest studier
- Houston, TX28 studier
- Boston, MA25 studier
- New York City, NY19 studier
- Los Angeles, CA16 studier
- Chicago, IL16 studier
- Durham, NC13 studier
- Columbus, OH12 studier
- Nashville, TN12 studier
- Baldwin Park, CA12 studier
- Philadelphia, PA12 studier
- Milwaukee, WI11 studier
- Atlanta, GA11 studier
- Seattle, WA11 studier
- Birmingham, AL10 studier
- Aurora, CO10 studier
- Edison, NJ9 studier
- Mountain View, CA9 studier
- Miami, FL9 studier
- Cincinnati, OH9 studier
- Portland, OR8 studier
- Queens, NY8 studier
- Dallas, TX8 studier
- New Haven, CT8 studier
- Buffalo, NY7 studier
- Denver, CO7 studier
- Washington, DC7 studier
- Tampa, FL7 studier
- Orange, CA7 studier
- Clifton, NJ7 studier
- Cedar Rapids, IA6 studier
- Omaha, NE6 studier
- Ann Arbor, MI5 studier
- Baltimore, MD5 studier
- Charlottesville, VA5 studier
- Memphis, TN5 studier
- Rochester, MN5 studier
- Cleveland, OH5 studier
- San Diego, CA5 studier
- Charlotte, NC5 studier
- Rochester, NY4 studier
Etter delstat
- Alabama10 studier
- Arizona7 studier
- California28 studier
- Colorado15 studier
- Connecticut11 studier
- Florida17 studier
- Georgia13 studier
- Illinois17 studier
- Indiana4 studier
- Iowa7 studier
- Kansas5 studier
- Kentucky6 studier
- Louisiana3 studier
- Maine3 studier
- Maryland11 studier
- Massachusetts28 studier
- Michigan8 studier
- Minnesota9 studier
- Missouri6 studier
- Nebraska6 studier
- New Jersey15 studier
- New Mexico3 studier
- New York26 studier
- North Carolina20 studier
- Ohio26 studier
- Oklahoma4 studier
- Oregon9 studier
- Pennsylvania15 studier
- Rhode Island4 studier
- South Carolina6 studier
- Tennessee14 studier
- Texas31 studier
- Utah4 studier
- Vermont4 studier
- Virginia7 studier
- Washington11 studier
- Wisconsin13 studier
Nylig oppdaterte studier
Offisiell studietekst (engelsk)
Rutgers University Study of the Genetics of Blood Cancers
RekruttererObservasjonsstudieFrivillige helsepersonell ønskes velkommen
Alder 18 til 110 · Alle kjønn · Oppdatert 1. okt. 2026 · NCT07714044Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
RekruttererObservasjonsstudie
Alder 0 til 38 · Alle kjønn · Oppdatert 1. okt. 2026 · NCT06131801Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)
RekruttererObservasjonsstudie
Alder 18 til 110 · Alle kjønn · Oppdatert 28. sep. 2026 · NCT00923507Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia
RekruttererFase 3
Alder 18 til 71 · Alle kjønn · Oppdatert 23. sep. 2026 · NCT07504458Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia
RekruttererFase 2
Alder 1 til 25 · Alle kjønn · Oppdatert 23. sep. 2026 · NCT05645718Natural History Study of GATA2 Deficiency and Related Disorders
RekruttererObservasjonsstudieFrivillige helsepersonell ønskes velkommen
Alder 2 til 100 · Alle kjønn · Oppdatert 22. sep. 2026 · NCT01905826A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
RekruttererFase 1/2
30 Days · Alle kjønn · Oppdatert 16. sep. 2026 · NCT04065399Chimeric Antigen Receptor Treatment Targeting CD70 (SEVENTY)
RekruttererFase 1
Opp til 75 år · Alle kjønn · Oppdatert 16. sep. 2026 · NCT06345027Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 16. sep. 2026 · NCT06824168A Prospective Trial of Dalbavancin-Based Prophylaxis in Children and Adolescents With High-Risk Leukemia
RekruttererFase 1
Opp til 25 år · Alle kjønn · Oppdatert 15. sep. 2026 · NCT06810583(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 15. sep. 2026 · NCT04996875A Phase II Study of the Menin Inhibitor Revumenib in Leukemia Associated With Upregulation of HOX Genes
RekruttererFase 2
Alder 12 og eldre · Alle kjønn · Oppdatert 11. sep. 2026 · NCT06229912Tools for Reducing Inequity in Acute Leukemia (TRIAL): Beta Testing
Rekrutterer
Alder 18 og eldre · Alle kjønn · Oppdatert 9. sep. 2026 · NCT06907797Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)
RekruttererFase 3
Alder 18 til 18 · Alle kjønn · Oppdatert 8. sep. 2026 · NCT07509151Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 2. sep. 2026 · NCT07249346Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP
RekruttererFase 2
Alder 1 til 18 · Alle kjønn · Oppdatert 2. sep. 2026 · NCT07354074Autologous CD22 CAR T Cells Following Commercial CD19 CAR T Cells in B Cell Malignancies
RekruttererFase 1
Alder 1 til 25 · Alle kjønn · Oppdatert 1. sep. 2026 · NCT06408194First-in-human Study of a New Treatment (4A10) for Patients With Relapsed or Hard-to-treat Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma, Focused on Safety and How the Drug Behaves in the Body and Early Signs of Effect.
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 1. sep. 2026 · NCT07586618Cognitive Aftereffects of Neurotoxicity in Children and Young Adults With Relapsed/Refractory Hematologic Malignancies Who Receive CAR T-cell Therapy
RekruttererObservasjonsstudieFrivillige helsepersonell ønskes velkommen
Alder 5 og eldre · Alle kjønn · Oppdatert 31. aug. 2026 · NCT05237986CIML NK Cells With Venetoclax for AML
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 28. aug. 2026 · NCT06152809Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 28. aug. 2026 · NCT07284433Assessing PI3K Gamma Inhibition With Azacitidine, Venetoclax and Eganelisib in Patients With Acute Myeloid Leukemia
RekruttererFase 1
Alder 18 til 90 · Alle kjønn · Oppdatert 26. aug. 2026 · NCT07439211Study of QUAIL-100 in Pediatric and Young Adult Participants With High-Risk Hematologic Malignancies Who Have Received a Hematopoietic Stem Cell Transplantation
RekruttererFase 1
18 Months – 39 Years · Alle kjønn · Oppdatert 21. aug. 2026 · NCT07573111Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 20. aug. 2026 · NCT07007312Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 20. aug. 2026 · NCT06001788Fra ClinicalTrials.gov, data hentet 4. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.